Treatment of premenstrual syndrome, including premenstrual tension and depression.
Treatment of puerperal depression.
Luteal phase support as part of an Assisted Reproductive Technology (ART) treatment for women.
Progesterone is added to estrogen replacement therapy to reduce the risk of cancer of the uterus.
Progesterone is also used as part of combination hormone replacement therapy with estrogens to reduce menopause symptoms (such as hot flashes).
In women who are not pregnant and not going through menopause, this medication is used to restore normal menstrual periods that have stopped for several months amenorrhea.
For the treatment of premenstrual syndrome and puerperal depression:
200mg daily to 400mg twice a day, by vaginal or rectal insertion. For premenstrual syndrome commence treatment on day 14 of menstrual cycle and continue treatment until onset of menstruation. If symptoms are present at ovulation commence treatment on day 12.
For luteal phase support as part of an ART treatment:
400 mg administered vaginally twice a day starting at oocyte retrieval. The administration of should be continued for 38 days, if pregnancy has been confirmed.
Use in special populations: There is no experience with use of in patients with impaired liver or renal function.
Paediatric population: There is no relevant use of in the paediatric population.
Diarrhoea and flatulence may occur with rectal administration
Menstruation may occur earlier than expected, or, more rarely, menstruation may be delayed.
Soreness, some leakage of the pessary base.
Vaginal haemorrhage, pelvic pain, metrorrhagia, ovarian enlargement, vulvovaginal pruritus.
Feeling cold, feeling of body temperature change, application site pruritus, discomfort.
Abdominal pain, Abdominal discomfort.